产品
编 号：F259029
分子式：C25H26ClN5O2
分子量：463.96
分子式：C25H26ClN5O2
分子量：463.96
产品类型
规格
价格
是否有货
结构图
CAS No: 2093400-18-9
产品详情
生物活性：
OTS186935 is a potent protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 regulates the production of γ-H2AX in cancer cells.
体内研究：
OTS186935 (10 mg/kg or 25 mg/kg; intravenously; once daily for 14 days) exhibits growth suppressive effects in human cancer cell line derived xenograft models.Animal Model:Female NOD.CB17-Prkdcscid/J mice(bearing MDA-MB-231 cells )
Dosage:10 mg/kg
Administration:Intravenously; once daily for 14 days
Result:Tumor growth inhibition of 42.6% on day 14.
Animal Model:Female BALB/cAJcl-nu/nu mice (bearing A549 cells)
Dosage:25 mg/kg
Administration:Intravenously; once daily for 14 days
Result:Yielded a tumor growth inhibition of 60.8% without significant body weight loss or toxicity.
体外研究：
OTS186935 inhibits A549 cell growth with an IC50 of 0.67 μM.
OTS186935 is a potent protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 regulates the production of γ-H2AX in cancer cells.
体内研究：
OTS186935 (10 mg/kg or 25 mg/kg; intravenously; once daily for 14 days) exhibits growth suppressive effects in human cancer cell line derived xenograft models.Animal Model:Female NOD.CB17-Prkdcscid/J mice(bearing MDA-MB-231 cells )
Dosage:10 mg/kg
Administration:Intravenously; once daily for 14 days
Result:Tumor growth inhibition of 42.6% on day 14.
Animal Model:Female BALB/cAJcl-nu/nu mice (bearing A549 cells)
Dosage:25 mg/kg
Administration:Intravenously; once daily for 14 days
Result:Yielded a tumor growth inhibition of 60.8% without significant body weight loss or toxicity.
体外研究：
OTS186935 inhibits A549 cell growth with an IC50 of 0.67 μM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备